Arlington Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Arlington Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-81	Closed	-$7K	–	177
2020 Q1	$7K	Hold	81	–	–	﹤0.01%	170
2019 Q4	$7K	Buy	+81	New	+$6.12K	﹤0.01%	205
2019 Q1	–	Sell	-81	Closed	-$7K	–	200
2018 Q4	$7K	Buy	+81	New	+$7.71K	﹤0.01%	175

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Arlington Partners's BMRN Position: Q2 2020 in Review

Arlington Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2020, closing a stake of 81 shares — an estimated $7K sold.

Arlington Partners first reported a position in BMRN in Q4 2018 and held it in 3 quarters. The position peaked at $7K in Q1 2020. 527 funds tracked by Wall St. Rank hold BMRN as of Q2 2020.

Arlington Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Arlington Partners sold 81 BioMarin Pharmaceuticals shares in Q2 2020, an estimated $7K.
Arlington Partners first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Arlington Partners's BioMarin Pharmaceuticals position peaked at $7K in Q1 2020.
527 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2020.

Based on Arlington Partners's 13F filing for Q2 2020, filed 13 Jul 2020.